Intellia TherapeuticsNTLA +1.64%70 PB Ratio is 3.01 as of Jun. 24, 2026, which is 3% above its 10-year median of 2.91. GuruFocus rates NTLA with a GF Score™ of 70/100 and a GF Value™ of $20.67 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Intellia Therapeutics ranks worse than 52.15% on this metric.
The historical rank and industry rank for Intellia Therapeutics's PB Ratio or its related term are showing as below:
NTLA'
s PB Ratio Range Over the Past 10 Years
Min: 0.88 Med: 2.91 Max: 24.41
Current: 3
During the past 12 years, Intellia Therapeutics's highest PB Ratio was 24.41. The lowest was 0.88. And the median was 2.91.
NTLA's PB Ratio is ranked worse than 52.15% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs NTLA: 3.00
During the past 12 months, Intellia Therapeutics's average Book Value Per Share Growth Rate was -31.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.00% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Intellia Therapeutics was 38.20% per year. The lowest was -25.90% per year. And the median was 3.90% per year.
Back to Basics: PB Ratio
Intellia Therapeutics (NAS:NTLA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intellia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Intellia Therapeutics (NTLA) has a PB Ratio of 3.01 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Intellia Therapeutics and its competitors. This is near median its historical median of 2.91. Over the past decade, Intellia Therapeutics' PB Ratio has ranged from 0.88 to 24.41. According to the industry distribution chart, Intellia Therapeutics ranks #643 out of 1233 companies in the Biotechnology industry, placing it in the top 52.1%.
Is Intellia Therapeutics' PB Ratio too high?
Intellia Therapeutics' current PB Ratio of 3.01 is near median its 10-year median of 2.91. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 24.41. The Biotechnology industry median PB Ratio is 2.83. Intellia Therapeutics' value of 3.01 is 6.4% above this industry median. Based on the distribution chart, Intellia Therapeutics ranks #643 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' PB Ratio compare to AUPH and OCUL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #643 out of 1233 companies for PB Ratio. This places Intellia Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.83. Intellia Therapeutics' value of 3.01 is 6.4% above this benchmark. Historically, Intellia Therapeutics' own PB Ratio has ranged from 0.88 to 24.41 over the past decade. While the company's 10-year median is 2.91 vs. the industry median of 2.83, Intellia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intellia Therapeutics's current PB Ratio of 3.01 is 6.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Intellia Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intellia Therapeutics's current PB Ratio is 3.01, which is near median its own 10-year median of 2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.67, compared to a current price of $15.51 — trading 25% below its estimated fair value. The current PB Ratio is 3.01, which is near median its 10-year median of 2.91 and 6.4% above the Biotechnology industry median of 2.83. Intellia Therapeutics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current PB Ratio is 3.01 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $15.51 is trading 25% below its estimated GF Value™ of $20.67.
GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.
Key valuation signals for NTLA:
PB Ratio: 3.01 (near median its 10-year median of 2.91)
GF Value™: $20.67 vs. price of $15.51 (25% below fair value)
Industry Position: 6.4% above the Biotechnology median (#643 of 1233)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
